Investors Buy Large Volume of Veru Call Options (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU - Get Free Report) saw unusually large options trading activity on Tuesday. Traders purchased 8,511 call options on the company. This is an increase of approximately 500% compared to the average volume of 1,418 call options.

Institutional Trading of Veru

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zacks Investment Management purchased a new position in Veru during the third quarter valued at $25,000. Gladstone Institutional Advisory LLC grew its position in shares of Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company's stock valued at $44,000 after purchasing an additional 14,500 shares in the last quarter. Weaver Consulting Group increased its holdings in shares of Veru by 41.0% in the fourth quarter. Weaver Consulting Group now owns 69,705 shares of the company's stock worth $45,000 after purchasing an additional 20,280 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company's stock worth $51,000 after buying an additional 42,997 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company's stock valued at $74,000 after buying an additional 56,736 shares during the last quarter. Institutional investors own 47.16% of the company's stock.

Veru Stock Performance

Shares of VERU traded up $0.11 during mid-day trading on Tuesday, reaching $1.09. The stock had a trading volume of 6,568,082 shares, compared to its average volume of 2,757,087. The firm has a market cap of $159.55 million, a price-to-earnings ratio of -3.89 and a beta of -0.53. Veru has a 12 month low of $0.36 and a 12 month high of $1.92. The business has a fifty day moving average of $0.70 and a 200 day moving average of $0.80.

Veru (NASDAQ:VERU - Get Free Report) last issued its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%. On average, research analysts forecast that Veru will post -0.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VERU shares. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reissued an "outperform" rating and set a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.